Quintiles

Quintiles opens European headquarters in UK

Wednesday, October 12, 2011 10:42 AM

Quintiles has officially opened its new European headquarters in Reading, United Kingdom, bringing together employees from each of its four disciplines.

More... »

Quintiles names global head of clinical & data operations

Tuesday, October 11, 2011 10:59 AM

Quintiles has named Steven Skolsky global head of its clinical & data operations (CDO) unit, the core of the company’s clinical development division that monitors the clinical conduct at research sites and collects and manages data from thousands of patients in hundreds of clinical trials conducted around the world.

More... »

Survey: Mid-tier CROs shut out of post-marketing

Monday, October 3, 2011 08:02 AM

Large CROs garner 57% of the post-marketing studies currently being outsourced, while another 25% of that work is awarded to the few firms that specialize in safety. The remaining 19%? That’s scattered among numerous mid-sized CROs.

More... »

New technology earns Quintiles top 5 ranking

Monday, October 3, 2011 08:00 AM

Many companies brag about bringing innovative technology to the clinical trials industry. Quintiles doesn’t have to brag. The most recent InformationWeek 500 is doing that for it.

More... »

PPD names CEO, puts acquisition rumors in question

Monday, September 26, 2011 08:02 AM

PPD has named a new CEO, a move that strikes some in the industry as a little strange in the face of rumors that the publicly traded CRO is close to selling itself to a private equity firm.

More... »

Eisai partners with SFJ in new outsourcing model

Friday, September 9, 2011 11:30 AM

Eisai has put the late-stage clinical development, as well as the associated funding, of a candidate compound for thyroid cancer in the hands of SFJ Pharma, wholly subsidiary of a US-based company that specializes in getting innovative drugs to market in Japan, according to PharmaTimes.

More... »

PPD rumored to be in exclusive acquisition talks with D.C.-based private equity firm the Carlyle Group

Monday, August 22, 2011 08:02 AM

While many in the upper echelon of private equity investors have been courting CRO PPD, for now all but one have been shooed away: Washington, D.C.-based Carlyle Group.

More... »

PPD denies CRO merger rumors, but stays mum on possibility of private equity takeover

Monday, July 25, 2011 08:00 AM

In the wake of last week’s Wall Street Journal report claiming PPD might be putting itself on the block, the top-tier CRO responded with a statement that it is not discussing mergers with other CROs. But what about private equity firms?

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »

Survey: Biopharmaceutical industry needs innovation

Tuesday, July 12, 2011 12:12 PM

A new Economist Intelligence Unit survey sponsored by CRO Quintiles highlights the urgent need for biopharmaceutical industry innovation. The global survey comes as the biopharma sector reaches the patent cliff—this year and next, seven of the world’s 15 top-selling drugs, accounting for nearly $50 billion in sales in 2009, will go off-patent.

More... »